Skip to main content

Table 6 Comparison between the published studies and the current study

From: Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC)

First author [reference]

Number of patients

Histology

CCT

RT

Targeted therapy

RECIST assessment

Blood flow

Blood volume

Mean transit time

Permeability

Wang et al [23]

35

Epidermoid Adenocarcinoma

No

Yes

No

Response

p > 0.05

Wang et al [23]

12

Epidermoid Adenocarcinoma

Yes

No

No

Response Progression

Fraioli et al [24]

45

Adenocarcinoma

Yes

 

Bevacizumab

Response

 

 

Lind et al [25]

23

Adenocarcinoma

Epidermoid

Large cell

  

Sorafenib

Erlotinib

Response

   

Tacelli et al [26]

17

Adenocarcinoma

Yes

 

Bevacizumab

Response

 

 

Tacelli et al [26]

23

Adenocarcinoma

Epidermoid

Large cell

Yes

No

No

Response

 

 

Sudarski et al [27]

100

Adenocarcinoma

Epidermoid

Yes

No

No

Response Progression Stable

Sudarski et al [27]

100

Small cell

Yes

No

No

Response Progression Stable

Trinidad et al [current study]

7

Adenocarcinoma Epidermoid Large cell

Yes

Yes

No

Response

p > 0.05

p > 0.05

p > 0.05

p > 0.05

Trinidad et al [current study]

46

Adenocarcinoma Epidermoid Large cell

Yes

No

No

Response

 

 
  1. Changes by treatment in perfusion parameters in lung cancer reported by different published studies:↑ = significant increase; ↓ = significant decrease; ↕ = in some patients, the parameter increases and in other patients, it decreases; ↔ = there were no changes; p > 0.05 nonsignificant changes
  2. RECIST Response evaluation criteria in solid tumours